Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the …
BM Demaerschalk, DO Kleindorfer, OM Adeoye… - Stroke, 2016 - Am Heart Assoc
Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …
Absolute and relative contraindications to IV rt-PA for acute ischemic stroke
JE Fugate, AA Rabinstein - The Neurohospitalist, 2015 - journals.sagepub.com
Most of the contraindications to the administration of intravenous (IV) recombinant tissue
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …
plasminogen activator (rtPA) originated as exclusion criteria in major stroke trials. These …
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice
Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the
prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation …
prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation …
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review
SS Adam, JR McDuffie, TL Ortel… - Annals of internal …, 2012 - acpjournals.org
Background: New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs)
and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of …
and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of …
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and …
Dabigatran, apixaban, and rivaroxaban have been approved for primary and secondary
stroke prevention in patients with atrial fibrillation. However, questions have arisen about …
stroke prevention in patients with atrial fibrillation. However, questions have arisen about …
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator
Context Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in
ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an …
ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an …
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
Background and purpose Whereas intravenous thrombolysis (IVT) is allowed for acute
ischaemic stroke in patients on vitamin K antagonists with international normalized ratio≤ …
ischaemic stroke in patients on vitamin K antagonists with international normalized ratio≤ …
The new oral anticoagulants in clinical practice
WI Gonsalves, RK Pruthi, MM Patnaik - Mayo Clinic Proceedings, 2013 - Elsevier
Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for
decades. However, with the US Food and Drug Administration approval of new oral …
decades. However, with the US Food and Drug Administration approval of new oral …
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment
HC Diener, C Foerch, H Riess, J Röther… - The Lancet …, 2013 - thelancet.com
Systemic thrombolysis with alteplase is the only approved medical treatment for patients with
acute ischaemic stroke. Thrombectomy is also increasingly used to treat proximal occlusions …
acute ischaemic stroke. Thrombectomy is also increasingly used to treat proximal occlusions …
Use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who take non–vitamin K antagonist oral anticoagulants before …
Background: Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective
in improving outcomes in ischemic stroke; however, there are few data on the use of rt-PA in …
in improving outcomes in ischemic stroke; however, there are few data on the use of rt-PA in …